Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Not sure how the share price can rise if investors are prohibited from buying in the open market.
<<There could be a PPS rise as the filings get updated and we will have missed out on adding shares at lower prices.>>
We doubt that they would have released yesterday's filing without having a clear path towards getting the entire process completed and on time.
We would expect to see the other filings released over the next few weeks, and the company become compliant with SEC requirements for current reporting status, by the September 28th deadline.
It would certainly be impressive for any of these upcoming gene therapies to be counted among the "Top 10", but to have achieved "Top 5" status is extremely notable.
The fact that CRXM has long been ignored by Wall Street investors, has presented a unique opportunity for those who have been fortunate enough to discover this company before the general investing public does.
We can't wait for the rush to acquire shares, by those who are intelligent enough to put all of the pieces of this puzzle together.
The current price certainly does not reflect the true potential of this company, in our view.
https://altitradepartners.blogspot.com/2021/03/a-potential-billion-dollar-heart-drug.html
Correct. We were not implying a $700 billion market cap for BIOF. That number is the estimated Total Addressable Market, or TAM, on a global scale.
Just 5% of that would = $35 billion.
CTS 2.0 Potential Global Revenue Sources ~$700B
https://www.bluebiofuels.com/wp-content/uploads/2021/08/ALLM-Company-Presentation-FINAL-8_26_21.pdf
Are you sure that came from Schwab and not TD Ameritrade? According to sources, Schwab has not made any decision yet regarding their policy on SEC Rule 15c2-11 securities.
While it's true that Schwab owns TD Ameritrade, they have not integrated their systems yet, and continue to operate independent of each other.
Covid 19 & Heart Damage
The cells in the heart have angiotensin converting enzyme-2 (ACE-2) receptors where the coronavirus attaches before entering cells. Heart damage can also be due to high levels of inflammation circulating in the body. As the body’s immune system fights off the virus, the inflammatory process can damage some healthy tissues, including the heart.
Coronavirus infection also affects the inner surfaces of veins and arteries, which can cause blood vessel inflammation, damage to very small vessels and blood clots, all of which can compromise blood flow to the heart or other parts of the body. “Severe COVID-19 is a disease that affects endothelial cells, which form the lining of the blood vessels,”
https://www.hopkinsmedicine.org/health/conditions-and-diseases/coronavirus/heart-problems-after-covid19
In the initial stage of myocardial ischemia, lack of oxygen and nutrient supply results in biochemical and metabolic changes within the myocardium. Depletion of oxygen switches the aerobic cellular metabolism to anaerobic metabolism and impairs the oxidative phosphorylation pathway leading to mitochondrial membrane potential loss and subsequently decreases in production and inhibits the contractile function of the cardiomyocytes.
A clinical syndrome, named angina pectoris, is the chest pain or discomfort that persists as a result of failure to acquire the required amount of oxygen to the cardiac muscles. National Health and Nutrition Examination (NHANES) states that as of the time frame between 2003 to 2006, it has been estimated that 17.6 million Americans of age 20 and above have had CHD. The annual incidence of myocardial infarction was 935,000, and the overall prevalence of angina pectoris was found to be 4.6%. In 2006, CHD was responsible for every one in six deaths and is the leading cause of death in both of the sexes.
https://www.mdpi.com/2673-8392/1/2/28/pdf
Learn to ignore the background noise.
Remember, it is hard to soar with eagles when you listen to turkeys.
When it comes to investing...
https://realinvestmentadvice.com/the-5-laws-of-human-stupidity-how-to-be-a-non-stupid-investor/
That seems highly unlikely.
It’s comical that you think that someone would have inside information, but what’s even funnier is that you would ask them to disclose it on a public stock message board.
That post is opinion, not fact.
Here is the link to the reviews on Amazon.
https://www.amazon.com/Healthy-Habits-StrictionD-GlucohelpTM-Supplement/product-reviews/B087N6Y8PN/ref=cm_cr_arp_d_viewpnt_rgt?ie=UTF8&reviewerType=all_reviews&filterByStar=critical&pageNumber=1
Also, how many clinical studies can you find on Striction D? There are none.
There have been over 100 clinical studies, conducted over the past 20 years, on Fibersol, the active ingredient in Glucodown, which validate its efficacy. Furthermore, Fibersol is on the FDA list of approved dietary fibers.
Over 20 years of clinical research and almost 100 published studies contributed to demonstrating Fibersol’s physiological benefits. These studies outline how Fibersol helps maintain intestinal regularity, attenuate post-meal blood glucose levels and retain healthy post-meal serum triglycerides. Recent studies have also shown Fibersol to be a prebiotic fiber that provides an increased feeling of satiety. In addition, many studies have confirmed that Fibersol is well tolerated, even when tested at a consumption rate as high as 68 grams per day.
https://www.snackandbakery.com/articles/91772-fibersol-included-on-fda-approved-list-of-fibers
Like we said in an earlier post it’s “all hands on deck.”
There is no excuse for not getting this done.
It's simply too important.
They still have over a month to get this done. If they miss the September 28th deadline, then you can say that they broke their promise, but not until then.
We are confident that they will be successful in getting to current status before the due date.
https://altitradepartners.blogspot.com/2021/08/gene-biotherapeutics-sec-filing.html
Refractory Angina Market growth will enlarge since the efforts to understand better the mechanisms and functions of gene and cell-based therapies in cardiology are helping in findings better options for treatment. Also, with the increased Refractory Angina prevalence and unavailability of targeted therapy, the first drug to target this untapped market will significantly gain upon the opportunity. Several therapies in the Refractory Angina pipeline have the potential to drive the market. Some of the most prominent ones include IMB-1018972, CLBS-14 (Auto-CD34+ cells), Ad5FGF-4, AdVEGFXC1, among others. The emerging drugs can significantly improve the overall quality of life of patients. Some major players in the global Refractory Angina market in the late phase of clinical development are Caladrius, Angionetics Inc, Imbria Pharmaceutical, XyloCor, and others.
https://www.bloomberg.com/press-releases/2021-07-27/refractory-angina-market-to-increase-at-a-7-97-cagr-during-the-study-period-2018-2030-speculates-delveinsight
It makes no sense to provide additional details at the present moment.
It would most likely get lost at this point in time, and would provide no significant impact in the market.
Once they get their house in order, it would be more appropriate to disclose any material information that they may have acquired, along with plans for a path forward.
We doubt that it would even warrant getting mentioned in the 10-K unless there was preliminary data to support raising the issue in the first place.
So then, you don’t feel that the extremely strong revenue growth on Amazon has anything to do with the share price increasing?
First, nobody is getting free shares. Financing deals are done at a discount to the market price. Shares are not handed out for free.
Second, most OTC pink sheet companies are forced to resort to very unattractive financing options to raise capital, including floorless convertible toxic debt, also known as "death spiral" financing.
Be glad that there were investors willing to finance this company, on very reasonable terms, because without them you would be up Shitz Creek without a paddle.
It appears that the CEO and CFO of Blue Biofuels are not taking a salary at this point, so that they can preserve cash to continue to refine the CTS 2.0 technology.
Does anyone really believe that they would be putting all of their time and efforts into something (without receiving compensation) that they do not believe in, and, more importantly that doesn't work?
Many OTC pink sheet companies have management teams that milk, or even bilk, the company for all its worth, and could care less about the business and the interests of shareholders. They look at the company as their personal piggy-bank and do nothing but ingratiate themselves.
ALLM management is clearly aligned with the interest of the rest of the equity holders, since they obviously are looking at the end-game (payoff) from the stock appreciating significantly later on down the road.
Oh, and let's not forget that they were able to accomplish what seemed to be an insurmountable task; take a public company through Chapter 11 Bankruptcy, reorganize the company's capital structure, eliminate or negotiate down the toxic debt, and, most importantly, keep all of the shareholder equity intact.
For those who believe that these guys are incompetent, remember that without Mr. Slager and Mr. Santelli there would not even be a company at this point.
We think that these two gentlemen deserve accolades, not acrimony.
Our opinion is that the filings will get done before the 9/28 deadline.
At this point, it's all hands on deck.
Management understands the importance of getting this done, and done soon.
There is simply too much at stake. Failure is not an option.
Of course, that probably won't stop the nail biting going on among many CRXM investors.
Too long, actually.
Your claims that the selling over the past two years has come from those investors who participated in prior GLUC financing activities is just plain wrong.
We debunked that B.S. conspiracy theory when we pointed out that all of those shares that were issued are RESTRICTED.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=164971684
Do some research and see what that means.
NJM is correct that a few investors have now converted their preferred shares into common. However, before they can sell them, the shares have to be cleared by the Transfer Agent, and then deposited into their respective brokerage accounts. That is not always an easy thing to do, given the fact that GLUC is a penny stock.
A simple e-mail, or call, to the CEO of Glucose Health, Inc. would probably help explain all of this, and give investors a better understanding of what has really been happening here.
<<"That's what I have been saying for a long time. There's only a few people making money on this stock and it's the group that gets their shares for nearly nothing.">>
For those who wish to know more about Rule 15c2-11 deadline, and its ramifications for non-reporting OTC pink sheet companies:
https://www.securitieslawyer101.com/2021/what-you-need-to-know-as-the-september-28-amended-rule-15c2-11-date-approaches/
The old saying that "a little knowledge can be dangerous" is especially appropriate for information found on social media, and particularly stock message boards.
We would caution investors from listening to those who formulate their opinions based on past knowledge, possibly gained from once being employed by ALLM, and not having a window into the current status of the company and the progress that has been made since they were let go.
We will, most likely, receive additional information from the company once it becomes appropriate for them to do so. Don't mistake the lack of any meaningful news with the idea that management is somehow sitting on their hands.
Building a business takes time, talent and money.
Once again, you are missing the mark. Biodiesel and jet fuel are the two main areas of focus, along with lignin.
The market opportunities are massive in all three of these areas.
We always understood that the goal was to get up-listed to one of the higher OTC tiers like OTCQB or OTCQX.
If they become a fully-reporting SEC company, why would they want their stock to trade on the pink sheets?
If you want to see a real Lazarus-story for a company, check out Predictive Technology Group (PRED).
They survived a couple of Hindenburg hit pieces, ran into trouble with the SEC regarding an overly-optimistic press release pertaining to COVID-19 test kits, had their stock suspended for trading after being sanctioned by the SEC, got relegated to the grey market, had the SEC ultimately lift their trading restriction, and then got reinstated back to the pink sheets.
Quite a miracle, if you ask us.
https://altitradepartners.blogspot.com/2021/07/is-pred-ready-to-bounce-off-brutal-six.html
Closed at the HOD, up 16.3%. Nice.
With all due respect, attempting to predict future stock prices is a fool’s errand.
We’ll stick with what we do best; Microcap research and analysis.
GLTY
While we see tremendous long-term potential in CRXM, the types of gains that you are expecting in the next 12 months, in our view, are very unrealistic and likely won't happen.
Achieving gains of 20X, 30X or 50X will, most likely, take years to come to fruition.
We say this for a number of reasons:
First, we don't believe that there will be any real interest coming from investors until the company announces the starting date of the Phase 3 clinical trials.
Before they are able to do that, they are going to need to create the financing mechanism to be able to fund the trials. That is going to be a very important aspect to the company's overall strategy moving forward.
It's extremely unlikely that they will use CRXM stock as the financing mechanism. With the share price where it is, that wouldn't make much sense, and would create massive dilution. We doubt that would be acceptable to CRXM management or Nostrum.
More likely it would be some sort of revenue sharing arrangement or licensing deal, based on global sales.
When we last looked at the balance sheet, the company was starved for cash (see page 42 of the Super 10-K) just to continue their operations, and the "going concern" clause is in the auditor's report for a reason.
The updated financials are critical, but we doubt that there will be any significant updates in them that would attract buyers. At this point, it is merely a perfunctory exercise to satisfy regulators and keep the company from falling into a OTC Markets black hole.
Getting off the pink sheets will also be important, but remember that with that, along with re-establishing themselves as a fully-reporting company, will come significant ongoing accounting and regulatory
costs.
The company has very limited revenues at this point, and it will probably remain that way for at least the next couple of years.
Perhaps with the royalty payments from the sale of the Excellagen product, they will receive some of the $3.35 million that CRXM is owed from Olaregen Therapeutix, Inc. We think, that $3.35 million number in royalty payments to CRXM will most likely take years to reach.
Remember, that CRXM receives royalty payments of only 10% on Excellagen, so it would take total global sales of $33.5 million to hit that $3.35 million number.
The Phase 3 trial is probably not going to be completed until sometime in late 2022 or early 2023, and of course as we all know there is no guarantee of receiving final approval from the FDA.
Lastly, we would point out that this stock is now held mostly by those investors with a short-term focus. Even if the shares do head north in a heartbeat (no pun intended), that advance will most likely be met with a substantial amount of selling from the new shareholder base that could care less about waiting 2-3 years for the big payoff.
You may get an initial spike somewhere along the line, but it probably would fade very fast and settle back down after the sellers have taken their short term profits.
While we share your overall enthusiasm for CRXM, we just don't see enough happening in the next 12-months to get major traction in the stock price, to the high levels that you are expecting.
Please feel free to offer a rebuttal, if you are so inclined.
Someone was definitely painting the tape near the EOD.
Unfortunately, it's going to be hard to cover up all of that red today.
Down volume topped up volume over 3X
CRXM Volume Analysis
https://ih.advfn.com/stock-market/USOTC/taxus-cardium-pharmaceut-pk-CRXM/trades
Not sure that the bottom is in yet on CRXM.
Waterfall selling appears to be starting.
We've learned not to try to catch a falling knife.
Better to wait until it hits the ground first, and then pick it up.
Wow, a $17 buy order.
Bet you needed to break open your piggy bank for that trade.
Those who are upset and sold their shares will really be in for a self-flagellation once this thing takes off.
Nobody held a gun to their head to buy, and the decision to sell rest squarely on their shoulders too.
Mature investors take responsibility for their own actions.
It doesn't work that way.
You are thinking with a retail investor's mind.
It's the difference between little league and the big leagues.
Do you really think that Nostrum bought into CRXM to make a few pennies?
They joined forces with CRXM to become a strategic partner. Strategic Partners don't trade their shares away in the open market. They hang on to them and continue to support the companies that they invest in.
Nostrum is in this for the long haul, and the huge payoff down the road that will likely come in 2-3 years.
We can tell you with a very high degree of certainty that Nostrum has not sold any of their position in CRXM.
<<They're aware their investment sucks. They got deep discount and likely already made their money back dumping those cheap shares on us. I too, would gamble with house money.">>
Perhaps you should pick up the phone and give Nostrum a call to let them know that they are also being scammed.
We are sure that they would appreciate your valuable insights.
LOL.